Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Thursday, February 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced a proposed public offering of common stock and warrants. This initiative aims to bolster its financial resources to further develop its gene editing therapies. The company focuses on sophisticated gene edits using its proprietary ARCUS platform, which includes gene insertion and excision capabilities.
Price reaction · baseline $18.5 (2024-02-29 close) · hit after-hours · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
-31.2%
day 1 · peak
-32.4%
day 3
-32.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The company is utilizing its proprietary ARCUS platform.
  • The proposed offering may enhance funding for future developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 29, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and

Frequently Asked Questions

What is the purpose of the public offering?

The public offering aims to enhance funding for developing gene editing therapies.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What types of gene edits can ARCUS perform?

The ARCUS platform can perform gene insertion, excision, and other sophisticated edits.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform public offering
Last updated: Feb 29, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →